Webinar: Impact of Molecular Testing for Toxigenic Clostridium difficile: Clinical and Laboratory Outcomes

[vzaar_embed vzvd=”1472864″ ]

[column size=”2/3″]

C. difficile infection (CDI) continues to be a major threat to patients, causing more than 2 million infections every year and resulting in >20,000 deaths in the US alone. Advances in molecular testing have greatly improved the accuracy of detecting toxigenic C. difficilein stool of patients suspected of CDI. This webinar will discuss laboratory benefits and clinical outcomes achieved by converting from traditional immunoassay methods to PCR-based testing.

Following the presentation, our speaker will take part in an interactive Q&A session. Please come prepared with your questions on this topic.

Information collected at registration may be shared with the sponsor.
For more information about our sponsor, please visit: www.BD.com

[column size=”1/3″]

Sponsored by:




[accordion title=”Featured Speaker” load=”show”]


Erik Munson, Ph.D.Erik Munson, Ph.D.

Director of Microbiology, Virology, Serology, Molecular Biology, Wheaton Franciscan Laboratory, Milwaukee, Wisconsin



CE instructions

The American Society for Clinical Laboratory Science is providing 1.0 contact hour of P.A.C.E.® credit for participants who attend the complete webinar. ASCLS P.A.C.E.® programs are accepted by the ASCP Board of Certification and all states, including California and Florida, as an approved provider for continuing education for recertification and licensure.

Use this link to get to the program evaluation.

Click this link
or copy paste into your browser: http://ascls.webedcafe.com/evaluation/612/5/199/Toxigenic-C-diff

Upon completion of the evaluation, you will be provided with a unique session code for the webinar and instructions on how to generate your certificate of attendance through the ASCLS CE Organizer online program.